Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Deals

Luca Healthcare Partners with Cambridge Cognition to Launch Cognitive Tools in China

Fineline Cube Dec 1, 2022

China-based digital health solutions provider Luca Healthcare has announced a strategic partnership and license agreement...

Company Drug

Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...

Company Medical Device

Assure Tech Wins Japanese PDMA Approval for Pen-Type COVID-19 Antigen Test

Fineline Cube Dec 1, 2022

China-based Assure Tech (Hangzhou) Co., Ltd (SHA: 688075) has announced receiving marketing approval from Japan’s...

Company Drug

Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials

Fineline Cube Dec 1, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...

Company Medical Device

Lepu Medical Wins NMPA Approval for Disposable Pressure Microcatheter

Fineline Cube Dec 1, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Policy / Regulatory

China’s NMPA Shifts to Electronic Drug Filings from January 2023

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...

Company Medical Device

Hainan Hospital Launches IBI’s Smartbone ORTHO for Bone Repair

Fineline Cube Dec 1, 2022

The clinical application of Smartbone ORTHO, a polyester collagen bone repair material introduced by Hainan...

Company Drug

CSL Vifor and Fresenius Kabi Win China Approval for Ferinject

Fineline Cube Dec 1, 2022

Swiss firm CSL Vifor and Germany’s Fresenius Kabi have announced the first regulatory approval in...

Company Deals

China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine

Fineline Cube Dec 1, 2022

Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...

Company Drug

Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study

Fineline Cube Dec 1, 2022

China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...

Company Deals

Henan Celnovte Biotechnology Raises RMB 100M in New Financing Round

Fineline Cube Dec 1, 2022

China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19

Fineline Cube Dec 1, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published...

Company Drug

Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study

Fineline Cube Dec 1, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...

Company Drug

Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA

Fineline Cube Nov 30, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...

Company Deals

Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline

Fineline Cube Nov 30, 2022

China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...

Company Deals

Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...

Company Deals

Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...

Company Drug

Luye Pharma Initiates Phase II Study for LY 03014 in China

Fineline Cube Nov 30, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...

Policy / Regulatory

China’s Drug-Eluting Stent Procurement Results Announced

Fineline Cube Nov 30, 2022

The national high-value medical consumables alliance procurement office has released the results of the successive...

Company Deals

Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement

Fineline Cube Nov 30, 2022

China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities...

Posts pagination

1 … 612 613 614 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.